Evidence that patients presenting with dyskaryotic cervical smears should be screened for genital-tract infections other than human papillomavirus infection

Author(s):  
M.A. Byrne ◽  
M.J. Turner ◽  
M. Griffiths ◽  
D. Taylor-Robinson ◽  
W.P. Soutter
2015 ◽  
Vol 2 (4) ◽  
pp. 101
Author(s):  
JanainaCristiana de Oliveira Crispim ◽  
CleineAglacy Nunes Miranda ◽  
PauloHenrique Lima ◽  
AnaKatherine Gonçalves ◽  
MariaDa Conceição de Mesquita Cornetta ◽  
...  

2002 ◽  
Vol 99 (Supplement) ◽  
pp. 87S
Author(s):  
Navin C. Bhojwani ◽  
Wendel R. Naumann ◽  
Mollie Elliot ◽  
Zahra Bahrani Mostafavi ◽  
Virginia Bond ◽  
...  

1990 ◽  
Vol 33 (2) ◽  
pp. 258-267 ◽  
Author(s):  
Bruce Patsner ◽  
David A. Baker ◽  
James W. Orr

2004 ◽  
Vol 6 (9) ◽  
pp. 1-21 ◽  
Author(s):  
Joakim Dillner ◽  
Darron R. Brown

Human papillomavirus (HPV) infection is the cause of squamous cell carcinoma of the uterine cervix. This causative relationship has provided the rationale and incentive for development of a prophylactic vaccine. Such a vaccine, if found to be effective, could reduce the need for cervical cancer screening and have a profound effect on the incidence of cervical and other anogenital cancers. This review begins by examining the basic biological and epidemiological principles relevant to the development of HPV preventative vaccines. It then summarises studies examining the use of vaccines to prevent HPV infection in animals and humans, and, finally, discusses some of the unanswered issues surrounding vaccine development against HPV infection and cervical cancer.


Sign in / Sign up

Export Citation Format

Share Document